Is Cerus Corporation (CERS) a Buy, Sell, or Hold?
NASDAQ : CERS
Cerus Corporation
$3.21 USD
$0.03 (0.94%)
- Volume
- 676.63K
- Average Volume
- 2.71M
- Market Capitalization
- $643.18M
- P/E Ratio
- -61.88
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $3.47
- Year Low
- $1.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.63
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Vivek K. Jayaraman |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | CERS |
| CUSIP | 157085101 |
| CIK | 0001020214 |
| Web | https://www.cerus.com |
| Phone | 925 288 6000 |
| Currency | USD |
| Employees | 275 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.44 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.63 |
| Quick Ratio | 1.06 |
| Cash Ratio | 0.26 |
Sales & Book Value
| Annual Sales | $206.13M |
| Price / Sales | 2.85 |
| Cash Flow | -0.01 |
| Price / Cash Flow | -522.21 |
| Price / Book | 9.12 |
Price Target and Rating
| Average Stock Price Forecast | $4.00 |
| High Stock Price Forecast | $4.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | -19.75% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.082 |
| Trailing P/E Ratio | -61.88 |
| PEG Ratio | -0.98 |
| P/E Growth | -0.98 |
| Net Income | -$15.63M |
| Net Margin | -4.29% |
| Pretax Margin | -4.13% |
| Return on Equity | -15.36% |
| Return on Assets | -4.28% |
Financials Score
| AltmanZ Score | -2.96 |
| Piotroski Score | 4.00 |
| Working Capital | 67.96M |
| Total Assets | 222.91M |
| Ebit | -1.09M |
| Market Cap | 643.18M |
| Total Liabilities | 154.62M |
Poll Results
About Cerus Corporation (NASDAQ:CERS) Stock
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, part ... icularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
2026-07-16 16:01:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.
2026-06-17 08:30:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress. “We look forward to highlighting how blood centers around the world are l.
Cerus Corporation Closes New Debt Facility of Up to $110 Million
2026-06-08 08:30:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consists of a 5-year term loan and an asset-backed revolving loan. The refinancing is expected to reduce annual cash interest expense by up to $3.5 million, reflecting lower borrowing costs and an approximately $30 million reduction in outstanding term loan balance. Initial proceeds from the loan, togethe.
2026-05-27 11:35:00
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company's two director nominees at the upcoming 2026 annual meeting in the below open letter to shareholders. *** May 27, 2026 Fellow Shareholders, I am an individual shareholder in Cerus managing my own capital. In light of the Company's negative returns and failure to achieve profitability over the past.
Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis
2026-05-10 07:51:01
Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231 million, which would imply promising 10%-12% YoY growth. IFC volumes rose about 120% YoY, making it the clearest current growth vertical beyond platelets.
Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript
2026-05-01 04:21:34
Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript
Cerus Corporation Announces First Quarter 2026 Financial Results
2026-04-30 16:01:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our INTERCEPT Fibrinogen Complex,” said William “Obi” Greenman, Cerus' president and chief executive officer. “As a result, we are raising our product revenue guidance for th.
2026-04-27 08:00:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device. “We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boute.
Frequently Asked Questions
-
What is the current Cerus Corporation (CERS) stock price?
-
Cerus Corporation(NASDAQ:CERS) stock price is $3.21 in the last trading session. During the trading session, CERS stock reached the peak price of $3.47 while $1.15 was the lowest point it dropped to. The percentage change in CERS stock occurred in the recent session was 0.94% while the dollar amount for the price change in CERS stock was $0.03.
-
CERS's industry and sector of operation?
-
The NASDAQ listed CERS is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of CERS?
-
Vivek K. Jayaraman | President, Chief Executive Officer & Director
William Greenman | Executive Chairman of the Board
Laurence Corash | Co-Founder & Chief Scientific Officer
Kevin D. Green | Vice President of Finance & Chief Financial Officer
Chrystal Jensen | Chief Legal Officer, General Counsel & Secretary -
How many employees does CERS have?
-
Number of CERS employees currently stands at 275. CERS operates from 1220 Concord Avenue, Concord, CA 94520, US.
-
Link for CERS official website?
-
Official Website of CERS is: https://www.cerus.com
-
How do I contact CERS?
-
CERS could be contacted at phone #925 288 6000 and can also be accessed through its website. CERS operates from 1220 Concord Avenue, Concord, CA 94520, US.
-
How many shares of CERS are traded daily?
-
The average number of CERS shares traded daily for last 3 months was 2.71M.
-
What is the market cap of CERS currently?
-
The market value of CERS currently stands at $643.18M with its latest stock price at $3.21